Immune to Cancer: The CRI Blog
-
New Cancer Immunotherapy Opdivo Approved by FDA
Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.
-
Faces of CRI: Introducing the People Who Make It Possible!
This holiday season, meet five Cancer Research Institute (CRI) staff members who want you to know why…
-
Breaking Through: 2014 Annual Report Highlights
Discover why this past year was one of many breakthroughs for the Cancer Research Institute with our…
-
FDA Approves New Immunotherapy for Leukemia
Amgen’s Blincyto was approved by the FDA, making it the first approved bispecific T cell engaging (BiTE)…
-
Wall Street Journal Article Profiles Cancer Immunotherapy ‘Super Survivors’
Cancer Research Institute scientists, and the patients they have treated, are the subject of a new article…
-
#GivingTuesday Breaks Record for Breakthrough Research
Cancer Research Institute extends a heartfelt thank you to our supporters who helped raise over $96,000 for…
-
Immunotherapy Featured on NBC Sports
Leukemia survivor Milton Wright highlighted during Thanksgiving's 49ers vs. Seahawks half-time show.
-
Immunotherapy for Blood Cancers: What to Look for at the Upcoming ASH Meeting
Look for the latest results from trials of PD-1 inhibitors and new developments in adoptive cell transfer.
-
Found: A Molecular Needle in the Cancer Haystack
New research by CRI scientists shows how genomic methods can be used to create a personalized cancer…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.